Single cell RNA-seq, TCR-seq and bulk TCR-seq on HNSCC patients treated with ICB
We performed single cell RNA- and TCR-sequencing (10x Genomics) on immune infiltrates (CD45+ cells) from 18 HNSCC patients enrolled in the IMCISION trial (Vos et al. 2021). Viable immune cells were isolated from pre-treatment and post-treatment primary tumor biopsies of 10 patients responding (1 partial pathological response and 9 major pathological responses) and 7 patients non-responding to anti-PD-1 and anti-CTLA4 combination immunotherapy. One patient treated with anti-PD-1 monotherapy (1 major pathological response) was included in the dataset. Bulk TCR-seq was performed on the PBMCs of responding patients, pre- and post-treatment.
- 137 samples
- DAC: EGAC00001003316
- Technology: unspecified
DAC for requesting access to the single cell datasets (scRNAseq and scTCRseq) and bulk TCR on HNSCC patients treated with neoadj NIVO/IPI.
To request access to the single cell datasets on HNSCC patients treated with neoadj NIVO/IPI, please provide the following information in your Data Access Request: - Recipient and Recipient Institution - Details of dataset requested, i.e. EGA Study and Dataset Accession Number(s) - Brief abstract of the Project in which the Data will be used (500 words max.) - All Individuals who will be allowed access to the requested datasets by the Recipient Institution. After receipt and review of your Data Access Request by the Data Access Committee, you will receive a Data Transfer Agreement to be completed, signed and returned to KT&C and the Data Access Committee, prior to being granted access to the requested dataset(s). For the avoidance of doubt, the Data Access Committee reserves the right to withhold granting access.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |